Therapeutic Pipeline
Our research and development programs span preclinical and clinical stages, advancing innovative treatments for complex CNS disorders through molecular precision.
| Category | Pipeline | Target | Indication | Pre-clinical | IND-enableing Studies | Clinical Experement | ||
|---|---|---|---|---|---|---|---|---|
| Phase I | Phase II | Phase III | ||||||
| i-Nas Small Molecule Platform | SP-101(IV) | NMDAR | Depression |
|
|
|
|
|
| Pain |
|
|
|
|
|
|||
| SP-101s(IN) | Depression/Pain |
|
|
|
|
|
||
| SP-102(Oral) | Depression/Pain |
|
|
|
|
|
||
| SP-103 | Depression/Anxiety |
|
|
|
|
|
||
| SynX Intracranial Delivery Platform | SP-201 | ApoE | Alzheimer's Disease |
|
||||
|
* IIT research
|
|
|
|
|||||
| SP-202 | Neurodegenerative Disease |
|
|
|
|
|
||
Compliance & Disclaimer
Important Notice: All products and drug candidates of Synphatec are currently in preclinical or clinical trial stages and have not been approved by the National Medical Products Administration (NMPA) or other regulatory authorities. They are not intended for clinical treatment use.
The information provided on this website is for reference purposes only and does not constitute any investment advice, partnership offer, or clinical efficacy claim. All clinical trial-related content is presented objectively based on trial stage and indication, without exaggeration of efficacy or cure rates.